Reports Q2 revenue $54.8M consensus $52.0M. “In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven computational technologies to accelerate molecular discovery,” said Ramy Farid, Ph.D., chief executive officer of Schrodinger (SDGR). “In addition to progressing several collaborative programs in our pipeline, we achieved an important milestone with the presentation of encouraging initial data for our MALT1 inhibitor, SGR-1505, and we expect to report initial data from our other two clinical programs in the fourth quarter.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Meta upgraded, PNC Financial downgraded: Wall Street’s top analyst calls
- Schrodinger assumed with an Equal Weight at Morgan Stanley
- Schrodinger Announces Board Elections and Approvals
- Positive Outlook for Schrödinger: Promising Phase 1 Data and Strategic Growth Initiatives Support Buy Rating
- Schrodinger’s Promising Clinical Data Offset by Market Concerns: Hold Rating Maintained